Volker Moebus

Affiliations

Department of Medicine II, Hematology & Oncology, Goethe University of Frankfurt, Frankfurt, Germany.

Réseau de co-auteurs

Antroula Papakonstantinou 1 collaboration

Alexios Matikas 1 collaboration

Nils Olof Bengtsson 1 collaboration

Per Malmström 1 collaboration

Elham Hedayati 1 collaboration

Guenther Steger 1 collaboration

Michael Untch 1 collaboration

Laila Hübbert 1 collaboration

Hemming Johansson 1 collaboration

Mats Hellström 1 collaboration

Michael Gnant 1 collaboration

Sibylle Loibl 1 collaboration

Richard Greil 1 collaboration

Theodoros Foukakis 1 collaboration

Jonas Bergh 1 collaboration

Paolo Nuciforo 1 collaboration

John Townend 1 collaboration

Martine J Piccart 1 collaboration

Shona Fielding 1 collaboration

Panagiota Gkolfi 1 collaboration

Sarra El-Abed 1 collaboration

Evandro de Azambuja 1 collaboration

Gustavo Werutsky 1 collaboration

Judith Bliss 1 collaboration

Marco Colleoni 1 collaboration

Alvaro Moreno Aspitia 1 collaboration

Henry Gomez 1 collaboration

Andrea Gombos 1 collaboration

Maria A Coccia-Portugal 1 collaboration

Ling-Ming Tseng 1 collaboration

Georg Kunz 1 collaboration

Guillermo Lerzo 1 collaboration

Joohyuk Sohn 1 collaboration

Vladimir Semiglazov 1 collaboration

Cristina Saura 1 collaboration

Judith Kroep 1 collaboration

Antonella Ferro 1 collaboration

David Cameron 1 collaboration

Richard Gelber 1 collaboration

Jens Huober 1 collaboration

Serena Di Cosimo 1 collaboration

A Matikas 1 collaboration

T Foukakis 1 collaboration

V Moebus 1 collaboration

R Greil 1 collaboration

N-O Bengtsson 1 collaboration

G G Steger 1 collaboration

M Untch 1 collaboration

H Johansson 1 collaboration

M Hellström 1 collaboration

P Malmström 1 collaboration

M Gnant 1 collaboration

S Loibl 1 collaboration

J Bergh 1 collaboration

Volker Moebus

Affiliations

Publications (3)

Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients.

Réseau de co-auteurs